FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
ADHD On The Rise In US: 6 Percent Of Adults Affected, Treatment Disrupted Due To Drug Shortages
A new CDC report reveals that over 15.5 million U.S. adults have ADHD, with 71.5 per cent facing difficulties obtaining ...
You can now dress up as a ‘sexy Ozempic shot’ this Halloween
An online store has jumped on the Ozempic craze by releasing a “sexy” semaglutide injection costume just in time for ...
3 No-Brainer Growth Stocks to Buy in October
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
devdiscourse19h
Global Health Headlines: Disruptive Developments and Key Cases
This summary provides the latest updates in health news, including HIV cases from organ transplants in Brazil, Sanofi's ...
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The Jerusalem Post Blogs3h
Best Ozempic Alternatives to Burn Fat Naturally: OTC Compounded Semaglutide Options to Try
Continue reading to learn the best options for effectively achieving your weight loss objectives ... by the Food and Drug ...
How a medtech market opportunity is shaping up for wearable neurotech
When you think of brain stimulating medtech, startups building wearables as therapeutics probably aren't the first thing that ...
Daily Montanan11h
FDA gets drugs out faster, but some work only ‘marginally’ better and are more expensive
A program to accelerate drug trials often provides the market with new drugs that are only marginally more effective, but ...
10 Biggest Stocks with Negative Beta to Consider
Beta is a measurement of market risk or volatility that indicates how much the price of a stock tends to fluctuate up and ...
Deutsche Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU)
In a report released on October 10, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research ...
Morningstar12h
Obesity Drug Market: The Next Wave of GLP-1 Competition
New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...